AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01370551
Drug: Estriol 0.03 mg, lyophylized lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
Trial: NCT00375713
Drug: Standard topical steroid (1% hydrocortisone) ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
Trial: NCT01019941
Drug: CKD-810, Taxotere inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
Trial: NCT01019941
Drug: CKD-810, Taxotere inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
Trial: NCT00574015
Drug: hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hydrocodone 10 mg/acetaminophen 650 mg
Trial: NCT02998190
Drug: Single Ascending Doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02998190
Drug: Multiple Ascending Doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04035031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
Trial: NCT02076711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00058747
Drug: Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by mouth (orally) each day for a period of 14 days.
Trial: NCT00002487
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02841163
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Trial: NCT03447873
Drug: Continue with triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To continue with triple therapy
Trial: NCT03447873
Drug: Switch to DTG + 3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to dolutegravir + lamivudine once daily
Trial: NCT01542788
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT01542788
Drug: Placebo to match SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match SOF was administered orally once daily.
Trial: NCT01542788
Drug: Placebo to match RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RBV was administered orally twice daily.
Trial: NCT01507740
Drug: Suntent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
Trial: NCT00829998
Drug: Sonata® 10 mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg, single-dose fasting
Trial: NCT00163293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide placebo-matching metered-dose inhaler
Trial: NCT00285779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02466919
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy
Trial: NCT00791648
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1.
Trial: NCT02443935
Drug: MGN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg s.c. twice weekly for 4 weeks
Trial: NCT02443935
Drug: MGN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg s.c. twice weekly for 24 weeks
Trial: NCT00529542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo caplet per day for six weeks.
Trial: NCT01872884
Drug: Sevorane Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevorane Remifentanil
Trial: NCT01872884
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil
Trial: NCT02104193
Drug: simvastatin in addition to radiation therapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Trial: NCT02746315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04348474
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Trial: NCT02793960
Drug: topical BPM31510 3.0% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of drug to lesions of epidermolysis bullosa
Trial: NCT00793520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral administration of placebo for 5 weeks.
Trial: NCT04329884
Drug: intra-articular corticosteroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
Trial: NCT04461886
Drug: NPC-12G gel
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-12G gel is containing 0.2% Sirolimus
Trial: NCT02752542
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
Trial: NCT01090596
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg naproxen, twice daily for 7 days
Trial: NCT01090596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab,twice a day for a seven days
Trial: NCT02260037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00772057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets given two times daily.
Trial: NCT00995787
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
Trial: NCT00995787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
Trial: NCT00931281
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, QD or BID, 14 days, ascending doses
Trial: NCT00931281
Drug: Placebo for ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, QD or BID, 14 days
Trial: NCT00003249
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01144650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
Trial: NCT02385071
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 milligram (mg) SMV capsule with water under fed conditions.
Trial: NCT02385071
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
Trial: NCT00710099
Drug: nitroprussiate iontophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroprussiate iontophoresis
Trial: NCT04154722
Drug: Azithromycin Powder
RxNorm normalized name: azithromycin Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: syp azithromycin for10days
Trial: NCT04243486
Drug: UHE-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical shampoo containing active drug
Trial: NCT04243486
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical shampoo containing no active drug
Trial: NCT03183310
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
Trial: NCT02896205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given matching placebo for 6 months
Trial: NCT01668680
Drug: CAPECITABINE, CELECOXIB and METHOTREXATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
Trial: NCT00841139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet bd
Trial: NCT00557193
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00557193
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00557193
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00557193
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, IT, or PO
Trial: NCT00557193
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT04422496
Drug: HEC96719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study.
Trial: NCT00548548
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
Trial: NCT04326738
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N group received corresponding intravenous normal saline of1ml·kg-1 .
Trial: NCT00189137
Drug: ifosfamide and doxorubicin vs gemcitabine and docetaxel
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.
Trial: NCT04281667
Drug: Oral Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
Trial: NCT04281667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
Trial: NCT00725985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to cladribine tablets were administered.
Trial: NCT00725985
Drug: Rebif® new formulation (RNF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
Trial: NCT02546323
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg tablets, orally once daily for the duration of the 104-week treatment period
Trial: NCT02546323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
Trial: NCT00673920
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00673920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01071161
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin, tablets, during 12 weeks, three times a week, 250mg
Trial: NCT01071161
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00085527
Drug: depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03755193
Drug: SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of SERM and ELD in osteoporosis patients
Trial: NCT03755193
Drug: Bisphosphonates and ELD Edirol®Tablet 0.75ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of BP and ELD in osteoporosis patients
Trial: NCT03755193
Drug: ELD Edirol®Tablet 0.75ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of ELD in osteoporosis patients
Trial: NCT04306926
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
Trial: NCT00024934
Drug: B-Lymphocyte Stimulator (BLyS)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01461460
Drug: TR-701 FA 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablet of T-701 FA
Trial: NCT01461460
Drug: TR-701 FA 200 mg plus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of TR-701 FA with 5 tablet placebo
Trial: NCT01461460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo tablets
Trial: NCT03781479
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT04635852
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02921256
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02921256
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02921256
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01448616
Drug: Placebo Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints.
Trial: NCT01448616
Drug: Vaginal TFV Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
Trial: NCT01448616
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Trial: NCT01983111
Drug: tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets.
Trial: NCT00875446
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00875446
Drug: GSK1223249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V Infusion
Trial: NCT02009787
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU placebo tablets were taken daily for 6 months
Trial: NCT04380142
Drug: Placebo for Levodopa/Carbidopa (LD/CD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04380142
Drug: Levodopa/Carbidopa (LD/CD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral encapsulated tablet
Trial: NCT04380142
Drug: Placebo for ABBV-951
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for continuous subcutaneous infusion (CSCI)
Trial: NCT00654732
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03880357
Drug: Taclonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Trial: NCT03880357
Drug: Placebo topical suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Trial: NCT01481610
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
Trial: NCT01481610
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
Trial: NCT03577457
Drug: ATD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Trial: NCT03577457
Drug: intranasal placebo treatment (placebo-control for oxytocin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo nasal spray
Trial: NCT03577457
Drug: oral placebo treatment (placebo-control for ATD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Trial: NCT04426474
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.